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Abstract
Background: MicroRNA (miRNA) expression is broadly altered in cancer, but few studies have investigated miRNA
deregulation in oral squamous cell carcinoma (OSCC). Epigenetic mechanisms are involved in the regulation of .30 miRNA
genes in a range of tissues, and we aimed to investigate this further in OSCC.
Methods: TaqManH qRT-PCR arrays and individual assays were used to profile miRNA expression in a panel of 25 tumors
with matched adjacent tissues from patients with OSCC, and 8 control paired oral stroma and epithelium from healthy
volunteers. Associated DNA methylation changes of candidate epigenetically deregulated miRNA genes were measured in
the same samples using the MassArrayH mass spectrometry platform. MiRNA expression and DNA methylation changes
were also investigated in FACS sorted CD44high oral cancer stem cells from primary tumor samples (CSCs), and in oral rinse
and saliva from 15 OSCC patients and 7 healthy volunteers.
Results: MiRNA expression patterns were consistent in healthy oral epithelium and stroma, but broadly altered in both
tumor and adjacent tissue from OSCC patients. MiR-375 is repressed and miR-127 activated in OSCC, and we confirm
previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in
tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44high oral CSCs. Aberrant
miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral
rinse and saliva from healthy volunteers, suggesting a potential clinical application for OSCC specific miRNA signatures in
oral fluids.
Conclusions: MiRNA expression and DNA methylation changes are a common event in OSCC, and we suggest miR-375, miR-
127, miR-137, the miR-200 family and miR-205 as promising candidates for future investigations. Although overall activated
in OSCC, miR-200/miR-205 suppression in oral CSCs indicate that cell specific silencing of these miRNAs may drive tumor
expansion and progression.
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Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most
common human malignancy worldwide, and the incidence rate is
increasing, especially in younger people [1,2]. Over 400,000
individuals die from this disease every year, with 80% of deaths
occurring in developing countries [3]. Oral carcinogenesis is
believed to represent a multi-step process driven by the
accumulation of carcinogen-induced genetic changes, and it is
generally accepted that many of the cancer-associated gene
changes stem from the gain, loss or mutation of genetic
information [4]. However, it has become increasingly clear that
epigenetic events, heritable changes in gene regulation not related
to changes in the primary DNA sequence, may also play an
important role in development of cancer [5]. Many findings have
thus shown that human cancer, including OSCC, is not only a
polygenetic, but also a polyepigenetic disease [6,7].
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The most frequent and readily detectable epigenetic event in
cancer is DNA hypermethylation of tumor suppressor genes, with
hypomethylation associated activation of oncogenes being being
less observed phenomenon [5,8]. CpG island hypermethylation in
human cancer has been shown for tumor suppressor, DNA repair,
hormone receptor, angiogenesis inhibitor and non-coding RNA
(ncRNA) genes [5]. In OSCC, silencing of p16INK4a, DAPK1, ABO,
MGMT, and CDH1 has been linked to increased DNA
methylation of the respective promoters, with frequencies varying
between 20% and 80% of oral primary tumors [9,10,11].
Interestingly, Hasegawa et al. [12] found that silencing of E-
cadherin by CDH1 CpG island methylation is related to smoking,
thus increased cancer risk in smokers may in part be a result of
tobacco induced epigenetic effects.
Moreover, the expression of microRNAs (miRNAs), a class of
,22 nt non-coding RNAs that regulate gene expression post-
transcriptionally [13], is broadly altered in most types of cancer
[14]. Many miRNAs are involved in important developmental
processes such as differentiation and epithelial to mesenchymal
transition (EMT), and are therefore often highly tissue and lineage
specific. MiRNA expression signatures can thus be used to classify
tumor subtype and origin and predict prognosis [15]. In addition,
miRNAs are relatively readily detectable compared to more
unstable and variable mRNAs, and some are also secreted by
exocytosis into bodily fluids, making them promising as diagnostic
and prognostic markers, as well as therapeutic targets [15].
Only a small number of reports have investigated miRNA
expression profiles in OSCC. Some important candidate miRNAs
in oral cancer etiology and progression have been proposed,
including loss of miR-34b, miR-100, miR-125b miR-137, miR-
193a and miR-203, which seems to occur specifically in OSCC
compared to normal oral mucosa [7,16]. Overexpression of miR-
21, miR-181b and miR-345 has been suggested as a signature of
malignant transformation of leukoplakia, for which histological
assessments have limited prognostic value [17]. However, and
further analyses of OSCC specific miRNA profiles, with insight
into the underlying regulatory mechanisms and functional
consequences, are required to consolidate current observations.
MiRNA deregulation can occur at both the transcriptional and
processing level, and aberrant DNA methylation patterns have
been implicated in altered expression of 30 or so miRNA genes in
different types of cancer [18]. A comprehensive bioinformatic
analysis found that about 50% of miRNA genes are associated
with CpG-islands [19], suggesting that many more miRNAs are
candidate targets of the DNA methylation machinery. There has
only been one extensive study of epigenetic silencing of miRNA
genes in oral cancer, which identified that repression of miR-34b,
miR-137, miR-193a and miR-203 is associated with increased
DNA methylation in oral cell lines and OSCC tumors [7].
Notably, increased miR-137 DNA methylation levels was linked to
poor OSCC survival rates [20], and was detected specifically in
patient oral rinse [21], suggesting it might provide a readily
detectable prognostic marker for OSCC.
Here, we aimed to further investigate miRNA deregulation with
a possible link to DNA hypermethylation in OSCC. MiRNA
expression patterns were analyzed by a combination of qPCR
arrays and individual miRNA assays for a panel of 25 OSCC
tumors with matched adjacent tissue and 8 control healthy oral
stroma and epithelium pairs. The DNA methylation status of
candidate epigenetically deregulated miRNA loci was subsequent-
ly measured using the semi-quantitative MassArrayH mass
spectrometry platform.
In general, both miRNA expression and DNA methylation
patterns were consistent across healthy controls, but highly
variable in both tumor and matched adjacent samples, thereby
highlighting tumor heterogeneity. Consistent with previous
reports, miR-137 methylation was increased in OSCC tumors.
MiR-375 was identified as strongly repressed and miR-127 as
activated in OSCC tumors, but this regulation appeared
independent of epigenetic change. There was a correlation
between miR-200 family and miR-205 expression and DNA
methylation levels across the sample panel, with concurrent
increased expression and DNA hypomethylation in tumors
compared to matched normal tissue. Interestingly, we observed
an epigenetically independent loss of miR-200 and miR-205
expression in CD44high cancer stem cell (CSC) populations sorted
from primary OSCC samples, suggesting that these miRNAs are
specifically repressed in cells driving tumor expansion and
progression. Finally, we show that miR-375 and miR-200a levels
are lower in OSCC patient oral rinse and saliva compared to
healthy controls. This demonstrates that miRNAs are present and
detectable in oral fluids, and could potentially be translated into
non-invasive OSCC clinical tests.
Materials and Methods
Sample preparation
Primary tissue samples. Frozen surgical OSCC specimens
from 25 patients were obtained from Odense University Hospital,
Denmark. The median age was 61 years (range 48–94 years), and
there were 9 females and 16 males. A tumor adjacent clinically
normal mucosa biopsy was also collected from all patients.
Hematoxylin-eosin staining of the histological sections was
performed to examine the ratio between cancer and normal
tissues. In 20 cases the cancer cells contributed 80% or more; these
tissue blocks were used directly for RNA preparation. In the 5
cases with lower tumor load, a laser microdissection system
(P.A.L.M.) was used to separate cancer cells from adjacent normal
tissue. Buccal mucosa samples were obtained from 8 healthy
volunteers (5 females and 2 males, median age 32 years, range 25–
62 years). To facilitate separation of healthy epithelium and
stroma, the healthy normal tissue samples were incubated in
2 mM EDTA buffer, as previously described by MacKenzie et al.
[22]. Informed written consent was obtained individually and the
research was approved by the Ethics Committee in Region Middle
Jutland according to Danish legislation (M-20110028). The full
name of the ethics committee is ‘‘The Central Denmark Region
Committees on Biomedical Research Ethics’’ (Danish name is ‘‘De
Videnskabsetiske Komite´er for Region Midtjylland’’, homepage:
www.komite.rm.dk).
Oral rinse (Buccal cells) collection. Careful brushing of
teeth and abstinence from food and drinking was required 1 hour
before sample collection. The mouth was cleaned by water and
subsequently rinsed with 10 ml PBS for 30–60 seconds. PBS
collection was repeated 4 times. The 40 ml total solution was
divided into 2 portions, centrifuged at 10,000 rpm for 10 min, and
the supernatant removed. One pellet was snap frozen at 280uC
for DNA purification and the other was dissolved in 1 ml RNA
later reagent (Qiagen, Copenhagen), kept at room temperature for
24 hours, and then stored at 220uC until RNA purification.
Saliva collection. Immediately after mouthwash collection,
,2 ml saliva was collected and divided into 2 portions. One was
snap frozen at 280uC for DNA purification. The other portion
was mixed with 5 ml RNA Protect Saliva reagent (Qiagen,
Copenhagen), kept at room temperature for 24 hours, and then
stored at 220uC until RNA purification.
Oral rinse and saliva were collected totally from 15 OSCC
patients and 7 healthy volunteers.
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RNA and DNA isolation
Total RNA from primary samples, oral fluids and cell lines was
purified using either TRIzolH RNA extraction reagent (Invitrogen,
Copenhagen) or the RNeasyH kit (Qiagen, Copenhagen) accord-
ing to supplier’s protocol and stored at 280uC. RNA quality was
examined on a 2100 BioanalyzerH chip (Agilent, Santa Clara CA),
and only samples with RIN .7 were used for TLDA analysis.
DNA from primary samples and oral fluids was column-purified
using the DNeasyH blood & tissue kit (Qiagen, Copenhagen)
according to the supplied protocol and stored in aqueous solution
at 220uC.
MiRNA expression analyses
MiRNA expression profiling was performed using the
TaqManH low density array (TLDA) qRT-PCR system (Applied
Biosystems, Foster City CA). TLDA v1.0 Early Access assays for
368 mature miRNAs, and was performed as per manufacturer’s
protocols. In brief, 0.5–1 mg total RNA from primary samples
were reverse transcribed with pools of miRNA specific RT-
primers, and the resultant cDNA was subjected to real-time
reverse transcription quantitative qRT-PCR using specific
forward primers and TaqManH fluorescent probes in an array
format. RNU48 was selected for normalization based on current
literature [23] and our own experimental validations, indicating
that RNU48 was the most reliable reference with consistent
expression for all samples (Fig. S1). Initial analyses were
performed using SDS software (Applied Biosystems). Statistical
tests for changes in expression (via Cts) were performed using
moderated t-tests without multiple testing corrections using the
R limma package [24]. Mature miRNAs were deemed
differentially expressed at p,0.05 and a 2fold change of
$1.5. Agglomerative hierarchical clustering of the miRNA
expression profiles was performed using the Cluster 3.0
software, requiring a miRNA to be detected in a minimum of
10 samples to be included.
Specific miRNA expression was determined by miRNA
TaqManH qRT-PCR assays (Applied Biosystems) according to
supplier’s protocol using 10 ng total RNA, and run in triplicates
on a LightCyclerH 480 (Roche, Basel Switzerland). As for the
TLDA profiling, expression was normalized to RNU48 (22DCt)
(TaqManH assay, Applied Biosystems) or miR-191 for oral fluid
samples. The latter was chosen because miR-191 is secreted and
robustly detectable in 12 different body fluids [25].
CpG cluster prediction
Regions significantly enriched for CpG dinucleotides were
predicted using the online sliding window algorithm CpGPlot in
the EMBOSS package from EMBL-EBI [26] (window=100 nt;
step = 1; Obs/Exp= 0.6; MinPC=50; Length= 50/100).
DNA methylation analysis
Bisulphite conversion of DNA was performed as described by
Clark et al. [27], using 0.1–2 mg DNA purified from primary tissue
and oral fluids. Bisulphite specific primers were designed by
standard principles for PCR amplicons in the 200–400 bp range
(Table 1), adding forward and T7 promoter reverse primer tags
required for Sequenom analysis according to specified require-
ments in [27]. PCR was carried out in duplicate at an annealing
temperature of 55uC, 40 cycles, using PlatinumH Taq DNA
polymerase (Invitrogen). DNA methylation analysis of pooled
duplicate bisulfite PCR amplicons for all primary and oral fluid
samples was performed using the MassArrayH MALDI-TOF mass
spectrometry platform (Sequenom, San Diego CA) according to
supplier’s protocol and improvements described by Coolen et al.
[28]. The DNA methylation level was scored as percentage
methylation of individual CpG units (comprising one or more
CpG-sites) averaged across the full CpG regions, thus arriving at
an average percentage miRNA locus DNA methylation for each
sample.
Cell culture
All oral cell lines were obtained as a gift from Professor Erik
Dabelsteen, School of Dentistry, University of Copenhagen. Cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10–20% fetal calf serum (Invitrogen),
50 units/ml penicillin and 50 mg/ml streptomycin (both Sigma-
Aldrich, St. Louis MO) under standard cell culture conditions
(37uC, 5% CO2). For the DNA demethylation and histone
deacetylatse inhibition experiments, culture cells were treated with
1–3 mM 5-aza-2’deoxycytidine (5-Aza-dC) for 48 h or 3 mM 5-
Aza-dC for 24 h followed by 50 nM trichostatin A (TSA) for 24 h
(both Sigma-Aldrich), as described in Hinshelwood et al 2007 [29].
Statistical analyses
Statistical significance was determined by the Student’s t-test
using Microsoft ExcelH 2004. The paired test was used to assess
significance between tumor/matched adjacent normal and
Table 1. Bisulphite primers.
Name Fwd primer Re primer Amplicon size
miR-34b TTYGGTTTGTAGGTAGTGTTATTAGT CRAAACAAACTACRCAAA 194
mir-127 GAAGTTTAGAGGGTTTTGATTT ACCCCTAATATATATCCACCAA 356
miR-137 TGAAAAGAATAAGAAAGTGTTATTTTGGTA AACTCAACCCATCCCCAAAC 309
miR-155 GGGTGTTTTTTGGGGATTTAGT AAAAACAATCTCTTTTTCCACCC 249
miR-200ab-429 TTATGGGAGTTTAGGGGATATATT ATTCAAACCTACACAAATAAA 224
miR-200c-141 AAGGTTATTAGGGGAGAGGTTT CTTCAAACCCAAAATCCCTA 313
miR-203 GTYGGGTGGTTGTAGTAGGGT ACCCCTAACTATAACTCTAACTCCAAA 295
mir-205 GAGTGAAGTTTAGGAGGTATGGAGT CACTCCAAATATCTCCTTCATTA 189
miR-375 GTGATTTTTTGGTTTTGGTTTTT AAAACTAAACAAACAATATAAAAACACAC 277
mir-410 GGGAGGGTTTTTTGTAAGTAT CTCCCTTCAAATACCAAAAAAA 376
doi:10.1371/journal.pone.0027840.t001
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epithelium/stroma pairs, and the unpaired unequal variance
Welch’s t-test for patient vs. healthy control tissues.
Results
As an initial screen for deregulated miRNAs, we performed
TaqManH miRNA low density array (TLDA) analysis for 2 non-
metastatic and 2 lymph node metastasis tumor and matched
adjacent epithelium pairs from OSCC patients, as well as normal
oral epithelium and stroma from 2 healthy controls. Hierarchical
clustering of the miRNA profiles showed that non-metastatic
(patients 18110 & 11063) and metastatic (patients 17093 & 28169)
tumors, adjacent normal and healthy control tissues fall into
separate groups, indicating that a specific miRNA pattern is
associated with OSCC (Fig. 1). The miRNA signatures were most
broadly altered between OSCC tumors and healthy epithelium,
with the matched adjacent tissue and stroma clustering in between.
As such, although of epithelial phenotype, OSCC tumors appear
more distinct from their origin than endogenous differences in oral
epithelium and connective tissue, thus highlighting the compre-
hensive miRNA changes involved.
Epigenetically deregulated miRNAs in OSCC were subsequent-
ly predicted based on the observed expression patterns, the
presence of CpG elements nearby the respective miRNA loci and
current literature. This initial list of possible candidates consisted
of miR-34b, miR-127, miR-155, the miR-200 family (miR-
200abc, miR-141 and miR-429), miR-203, miR-205, miR-375
and miR-410. Although miR-137 expression was below the
detection limit for all samples in our initial screening, this was also
included as it has previously been associated with DNA
hypermethylation in OSCC [7,20].
The DNA methylation level of the respective miRNA loci was
assessed using the MassArrayH mass spectrometry platform for an
expanded panel of primary samples, consisting of 25 tumor/
matched normal and 8 healthy stroma/epithelium pairs (Fig. 2). A
broad spectrum of CpG methylation patterns were observed,
ranging from completely methylated to unmethylated, thus
demonstrating the dynamic range of the MassArrayH system.
Statistically significant differential methylation was observed
between tumor and matched normal and/or healthy epithelium
for the miR-127, miR-137, miR-200ab-429, miR-200c-141 and miR-
205 loci (Fig. 2), but no distinct differences were observed between
metastatic and non-metastatic tumors. MiR-375 remained un-
methylated across the sample panel (Fig. 2a), and miR-34b, miR-
155, miR-203 and miR-410 displayed unchanged or inconsistent
DNA methylation patterns (data not shown).
Having established a shorter list of epigenetically deregulated
candidates (miR-127, miR-137, the miR-200 family and miR-
205), we went on to measure their expression level in the full
sample panel by individual TaqManH miRNA assays. As the most
strongly repressed miRNA, miR-375 was also included (Fig. 2).
Similar to DNA methylation, miRNA expression patterns were
Figure 1. Hierarchical clustering of OSCC and healthy oral
tissue miRNA expression profiles. MiRNA expression profiling was
performed using TaqManH TLDA low density miRNA arrays for primary
tumor/matched normal adjacent pairs from 4 OSCC patients, as well as
normal epithelium and stroma from 2 healthy controls. The samples
encompass 2 non-metastatic tumors (18110T & 11063T), 2 metastatic
tumors (17093T & 28169T), 4 matched adjacent normal tissues (18110N,
11063N, 17093N & 28169N), 2 healthy connective tissue (stroma) (H14C
& H5C) and 2 healthy epithelium (H14E & H5E), respectively. Expression
was normalized to RNU48 (22dCt) and hierarchical clustering was
performed using Cluster 3.0. for relative miRNA levels, and is color
coded from bright green (undetected) to red (highest expression).
doi:10.1371/journal.pone.0027840.g001
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highly variable in the OSCC tumors and matched adjacent tissues,
but consistent in healthy normal epithelium and stroma. This
further illustrates broad changes in both miRNA expression and
DNA methylation in OSCC patients. Again, there were no clear
differences between metastatic and non-metastatic tumors for
these miRNAs. MiR-375 was confirmed as a strongly repressed
miRNA in OSCC, with 10 2fold decreased expression in tumors
compared to matched adjacent tissue, and a 1000 2fold change
when comparing to healthy epithelium (Fig. 2g). This miRNA is
probably epithelial specific, highlighted by 2 orders of magnitude
higher miR-375 expression in healthy epithelium than stroma.
MiR-137 remained undetected in all samples, suggesting that
mature miR-137 is silenced in oral tissues regardless of miR-137
CpG methylation status (data not shown).
The expression patterns of miR-127, the miR-200s and miR-
205, on the other hand, were more complex (Fig. 2h–k). Mature
miRNA levels were distinctly different in healthy oral epithelium
and stroma, reflective of miRNA tissue specificity. Although a
significant change was observed between tumor and matched
normal pairs, the adjacent tissues were overall more similar to
stroma than epithelium, indicating that both tumors and adjacent
epithelium may gain stromal-like features in OSCC patients
(Fig. 2h–k). MiR-127 appears to be a stroma specific miRNA, and
is present at lower levels in OSCC tumors than in corresponding
adjacent tissue, but overall upregulated in patients compared to
healthy epithelium. Consistent with previous reports, the miR-
200-family and miR-205 are most active in epithelium, and their
expression is increased in OSCC tumors compared to matched
adjacent normal (Fig. 2h–k) [30,31,32].
Neither in the healthy control tissues, nor in the tumor and
matched normal pairs, could changes in miR-127 expression be
accounted for by corresponding DNA methylation patterns, which
remained elevated throughout the sample panel. Rather, miR-127
repression was associated with a seemingly contradictory statisti-
cally significant pair-wise loss of methylation in tumor vs. adjacent
tissue (Fig. 2b). This phenomenon has also been observed in
prostate cell lines [33]. However, as the locus remains 75–80%
methylated, this might not affect transcription levels and could
merely be a result of broad, unspecific CpG methylation changes
in the tumors.
For the miR-200s and miR-205, however, expression and
methylation patterns were indicative of a role for epigenetic
regulation. In healthy controls, high expression correlated with low
DNA methylation in epithelium, with the reciprocal pattern
observed in stroma. Figure 3 highlights by pair-wise comparison
that activation of miR-200/miR-205 is strongly correlated with
overall decreased CpG methylation of the miR-200ab-429, miR-
200c-141 and miR-205 loci in OSCC patients. Thus, in line with
previous reports in cell lines and bladder and breast cancer
[34,35,36], the miR-200 family and miR-205 appears to be
coordinately epigenetically regulated in healthy and diseased oral
tissues.
Activation of the miR-200 family and miR-205 has also been
reported in other forms of cancer, however, their expression is less
prominent in invasive and metastatic tumors. This can be
explained by miR-200/205 targeting ZEB1 and ZEB2, which
are transcriptional repressors of E-cadherin and master regulators
of EMT [30,31]. In addition, miR-200/miR-205 repression leads
to activation of Notch signaling [37], and miR-200c also targets
BMI1, a regulator of stem cell renewal [35,38]. Reactivation of
miR-200c inhibits stem cell directed expansion of breast tumors in
mice [35], and miR-200c expression is low in head and neck
squamous cancer stem cells (CSCs) [38]. Repression of the miR-
200s and miR-205 therefore leads to silencing of E-cadherin and
BMI1, followed by EMT, loss of cell anchorage and cellular
dedifferentiation, probably inducing CSC formation [32,35,39].
To investigate a broader role of the miR-200 family and miR-205
regulation in OSCC, we therefore went on to investigate their
regulation in oral CSC populations.
The CSC hypothesis entails that a subpopulation of dediffer-
entiated stem-like cells drive tumor expansion and progression.
These cells have elevated levels of the cell surface marker CD44 in
a variety of cancers, including OSCC [38,40]. Here, oral CSCs
were enriched by FACS sorting the top 5% of CD44-positive cells
(CD44high) from 3 primary tumors. As reference, the bottom 5%
CD44-negative cells (CD44low) and populations from healthy
controls, were also isolated. Strikingly, miR-200 and miR-205
expression was 2–10 2fold lower in tumor CD44high CSCs
compared to the CD44low fraction, whereas no difference was
observed between healthy control CD44high and CD44low
populations (Fig. 4a–b). This CD44high specific miR-200/miR-
205 loss was not associated with increased DNA methylation. It
thus seems that, although overall activated in OSCC tumors, miR-
200 and miR-205 expression is specifically repressed indepen-
dently of epigenetic silencing in tumor driving CD44high oral
CSCs.
MiR-137 has also been linked to stem cell differentiation by a
number of studies [41,42,43], therefore we investigated expression
and DNA methylation of this miRNA in the CD44 sorted
populations as well (Fig. 4c–d). Unlike for the primary tissue
samples, in these purified populations mature miR-137 was readily
detectable. Expression was lower in cancer compared to normal,
with corresponding miR-137 CpG methylation levels of,80% and
,10%, respectively. This confirms previous reports of epigenetic
miR-137 silencing in OSCC, but suggests that this occurs in
specific cell types and may not be detectable in total, heterogenous
tumor samples. Moreover, an increase in miR-137 expression,
independently of altered DNA methylation, was observed in
patients’, but not healthy CD44high compared to CD44low cells. In
fact, cancer and normal CD44high cells displayed relatively similar
miR-137 expression, with the greatest difference between the
CD44low populations (Fig. 4c–d). The main miR-137 deregulation
may thus not occur in tumor and progression driving CSCs. In
addition, as for miR-200/miR-205, epigenetic mechanisms can
only partly account for miR-137 repression in OSCC.
Finally, in order to investigate possible diagnostic relevance, we
tested whether any of the OSCC specific miRNA expression and/
or DNA methylation changes could be used to distinguish patient
Figure 2. DNA methylation and expression patterns for candidate epigenetically deregulated miRNAs. MiRNA CpG methylation (a–f)
and expression (g–k) patterns in OSCC in and normal oral tissues. DNA methylation levels were measured using the MassArrayH mass spectrometry
platform for CpG enriched regions in themiR-375 (a),miR-127 (b),miR-200ab-429 (c),miR-200c-141 (d),miR-205 (e) andmiR-137 (f) loci in a panel of 25
OSCC tumor/matched adjacent pairs and 8 healthy control epithelium/stroma pairs. Values are presented as average percentage CpG methylation
across the full regions analyzed for each locus. Relative expression of miR-375 (g), miR-127 (h), miR-200abc (average) (i), miR-141 (j) and miR-205 (k)
was evaluated in the same samples by individual TaqManHmiRNA assays performed in triplicates and normalized to RNU48 (22dCt). Box plots indicate
the median value (horizontal line) and the 25th–75th percentile range (box) with whiskers at 1.56IQR. Values outside this range are shown as outliers
(points). P-values were determined by the paired two-tailed Student’s t-test for matched patient tumor/adjacent and healthy epithelium/stroma pairs
overall, and the unpaired two-tailed Student’s t-test for tumor vs. healthy epithelium.
doi:10.1371/journal.pone.0027840.g002
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and control oral fluids. Mature miRNA and DNA methylation
levels were assessed in RNA and DNA isolated from oral rinse and
saliva from 15 OSCC patients and 7 healthy subjects (Fig. 5).
When measuring secreted miRNA levels, it is no longer suitable to
use intracellular snoRNA (RNU48) for normalization. Therefore,
we selected miR-191 as a reference for profiling oral rinse and
saliva samples based on the notion that this miRNA is secreted
into a variety of body fluids and is considered a robust miRNA for
qPCR normalization purposes [25,44]. Consistent with repression
in tumors, miR-375 levels relative to miR-191 were lower in both
patient oral rinse and saliva (Fig. 2g & Fig. 5a). MiR-200a relative
to miR-191 levels were also decreased in patient oral rinse, but
remained unchanged in saliva (Fig. 5b).
Whereas miR-200c levels were stable across all oral fluid
samples, miR-200c-141 CpG methylation was significantly elevated
in patient oral rinse, but not in saliva. This is consistent with the
generally higher methylation of this locus observed for tumor and
matched adjacent tissue from OSCC patients compared to healthy
epithelium (Fig. 2d & Fig. 5c–d). Certain OSCC specific miRNA
and DNA methylation signatures are therefore both present and
detectable in oral fluids, and have potentially clinical diagnostic
application.
Discussion
According to our observations, miRNA expression and
corresponding DNA methylation patterns are tightly controlled
in, and often specific to, healthy oral epithelium and stroma. In
OSCC patients, on the other hand, these patterns are broadly
altered, representing variable changes occurring in both primary
tumor samples and matched adjacent tissue (Figs. 1–2). Therefore,
in line with previous work [7,16,45], it seems that OSCC is
associated with a range of aberrant epigenetic and miRNA
expression patterns. We did not identify any specific changes in
miRNA expression profiles or DNA methylation patterns between
non-metastatic and metastatic OSCC tumors. However, as the
miRNA expression profiles cluster separately based on global
signatures (Fig. 1), there are probably differences in miRNA
Figure 3. miR-200 and miR-205 expression and methylation differences in individual tumor vs. matched adjacent pairs. Expression
and DNA methylation was determined as explained in the legend to Figures 2, and represents the same data visualized as the difference between
individual pairs of tumor and matched adjacent epithelium. (a) miR-200a, miR-200b, miR-200c, miR-141 and miR-205 2fold change expression (+/2
SD), and (b) average % CpG methylation change of the miR-200ab-429, miR-200c-141 and miR-205 loci (+/2 SE). X-axis numbers are OSCC patient
identifiers.
doi:10.1371/journal.pone.0027840.g003
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species other than those investigated in detail here, such as for
instance miR-34, miR-21 and miR-203 (Fig. 1 and data not
shown).
Specifically, we identify miR-375 as a highly significantly
repressed miRNA in OSCC tumors compared to matched
adjacent normal tissues and healthy tissues from volunteers
(Fig. 2a). Loss of miR-375 has also been reported in gastric, liver
and breast cancers, and a putative tumor suppressor role has been
linked to a failure to repress the oncogenic miR-375 targets JAK2,
YAP, PDK1 and RASD1 [46,47,48,49]. Epigenetics have been
implied in miR-375 regulation in breast cancer cells, where local
depletion of DNA methylation and H3K9me2 and dissociation of
the transcriptional repressor CTCF leads to miR-375 upregulation
and subsequent activation of estrogen receptor a [47]. However,
miR-375 silencing does not appear to be associated with DNA
hypermethylation in OSCC (Fig. 2g).
As miR-375 silencing has been linked to a number of cancer types
and target oncogenes, it probably acts as a general tumor suppressor
miRNA. Although based on a small sample panel, this is, to our
knowledge, the first report of altered miR-375 levels in body fluids of
cancer patients. Clinical detection of repressed miR-375 levels may
therefore not be limited to oral fluids and OSCC diagnosis. It would
be interesting to investigate miR-375 presence in other bodily fluids,
such as plasma or urine, for various cancer forms in order to
establish a possible general diagnostic significance.
MiR-200a was also present at lower levels in oral rinse from
cancer patients compared to healthy controls, but remained
unchanged in saliva (Fig. 5b). Thus, oral rinse and saliva may have
different value in clinical detection, and both types of oral fluid
should probably be investigated independently when assessing
diagnostic potential. It is possible that the greater exposure of the
oral surface exfoliative buccal epithelia to environmental factors,
such as for instance tobacco, makes these cells more prone to
genetic and epigenetic aberrations. This suggests that oral rinse is a
more sensitive source for clinical detection of OSCC specific
miRNA and DNA methylation patterns than saliva, but this
notion must be investigated in further detail.
Moreover, we confirm the previous reports of miR-137 CpG
hypermethylation in OSCC [7,20]. Although statistically signifi-
cant, this increase was small in the primary samples (,15%,
Fig. 2f), but in the CD44 sorted pure cell populations miR-137
went from nearly fully methylated in cancer to unmethylated in
normal, with corresponding expression patterns of the mature
miRNA (Fig. 4c–d). However, contrary to Langevin et al. [21], we
did not detect increased miR-137 methylation in OSCC patient
saliva or oral rinse (data not shown). An epigenetically indepen-
dent increase in miR-137 was observed in CD44high CSCs
compared CD44low cells, consistent with a role in differentiation
[41,42]. This demonstrates that miR-137 must be regulated by
other mechanisms as well, which could explain why miR-137
Figure 4. miRNA expression and DNA methylation in oral cancer stem cells. MiR-200 family and miR-205 expression (a) and DNA
methylation (b), and miR-137 expression (c) and DNA methylation (d) in OSCC cancer stem cells (CSCs) purified by FACS sorting the 5% most CD44
staining cells from 3 primary samples (CD44high), compared to the 5% least staining cells (CD44low). Similar control non-CSC cells were sorted from 3
healthy individuals. Relative miRNA expression (+/2 SD) was determined by individual TaqManH miRNA assays normalized to RNU48 (22dCt), and
percentage CpG methylation levels (+/2 SE) across the indicated regions were measured using the MassArrayH mass spectrometry platform.
Statistical significance was determined by the paired one-tailed Student’s t-test for CD44high vs. CD44low cells from individual patients.
doi:10.1371/journal.pone.0027840.g004
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remains undetected throughout the primary sample panel
regardless of low DNA methylation in normal tissues (Fig. 2f).
MiR-127 was one of the first reported epigenetically regulated
miRNAs [50], but this does not appear to relate to miR-127
changes in OSCC. Rather, we observed highly variable expression
of this miRNA, associated with unchanged (adjacent normal vs.
healthy epithelium) or anti-correlated (tumor vs. adjacent) loss of
DNA methylation (Figs. 2b & 2h). Overall, miR-127 expression
was elevated in patient tissues compared to healthy epithelium,
suggesting a putative oncogenic role in OSCC. Moreover, miR-
127 expression, but not methylation, was much higher in healthy
stroma than epithelium, supporting that this miRNA normally
functions in oral connective tissues and is aberrantly activated in
squamous cell tumors (Figs. 2b & 2h).
In line with previous work by us and others in bladder, prostate
and breast cancer [34,35,36], the miR-200 family and miR-205
are coordinately regulated in both transformed and healthy oral
tissues. The miR-200s and miR-205 were also clearly epithelium
specific, and epigenetic silencing appears to be a normal event
preventing their expression in healthy stroma (Figs. 2d–f & 3c–d)
[30,31]. Consistent with a previous report of miRNA expression
patterns in squamous head and neck cancer cell lines [51], we also
observe that the miR-200 family and miR-205 are highly
expressed in four oral squamous cell lines (SCC9, SCC25,
SCC71 and CAL27; data not shown). However, there are
indications that these miRNAs are comparatively repressed in
poor prognosis disease [52]. Here, we observe miR-200/miR-205
activation in association with DNA hypomethylation in OSCC
tumors compared to matched adjacent epithelium, but no obvious
change between metastatic and non-metastatic tumors. Previous
reports have shown that E-cadherin is expressed in OSCC, but
fails to localize to the plasma membrane [53]. Hence, as opposed
to other cancer forms, miR-200 activation of E-cadherin
expression may not direct correct E-cadherin function in OSCC.
A recent study showed that the miR-200s can also promote
metastatic colonization through an E-cadherin independent
pathway via direct targeting of Sec23a [54]. As such, these tumors
may be highly aggressive and invasive despite elevated miR-200
expression in the tumor mass.
The specific silencing of the miR-200 family and miR-205 in
CD44high oral CSCs was not associated with increased DNA
methylation. Thus, other mechanisms are probably initiating the
primary repression of these miRNAs, with epigenetic silencing
being a secondary and more definitive event in the tumor mass
(Fig. 5a–b). The primary event could potentially be linked to EMT
specific transcription factors such as ZEB, Twist, Snail or Slug,
which have previously been associated with miR-200 regulation
[55]. Given their role in maintaining E-cadherin expression and
repressing Notch signaling, this primary silencing of miR-200/
miR-205 is probably important for acquiring the dedifferentiated
and migratory properties of tumor driving CSCs [35,38]. Indeed,
the miR-200 family and miR-205 are known to play complicated
Figure 5. miRNA expression and DNA methylation in oral rinse and saliva. (a) miR-375 (b) miR-200a and (c) miR-200c relative to miR-191
expression ratio, and (d) absolute miR-200c-141 DNA methylation level in oral rinse and saliva from 15 OSCC patients and 7 healthy controls. The box
plots represent the median value (horizontal line) and the 25th–75th percentile range (box) with whiskers at 1.56IQR. Values outside this range are
indicated as outliers (points). MiRNA ratio (+/2 SD) was determined by individual TaqManH miRNA assays, normalizing miR-375 to miR-191 Ct values
(22dCt). Percentage CpG methylation (+/2 SE) was measured using the MassArrayH mass spectrometry platform. P-values were determined by the
unpaired two-tailed Student’s t-test for OSCC patients vs. healthy controls.
doi:10.1371/journal.pone.0027840.g005
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roles in malignant transformation. They appear to be activated
during the transformation from normal tissue - to premalignant
lesion - to carcinoma in situ in order to maintain epithelial
properties, but then becomes repressed during mesenchymal
transition, which drives invasion and metastasis [32]. Specific
miR-200/miR-205 silencing in mesencymal-like oral CSCs, may
thus be an important driver of tumor invasion and recurrence.
The underlying mechanism of miR-200 and miR-205 deregula-
tion may therefore provide powerful complementary therapeutic
cancer targets.
Conclusions
In summary, we report novel candidate OSCC deregulated
miRNAs with associated DNA methylation patterns, and normal
miRNA expression in healthy oral epithelium and stroma. MiR-
375 is repressed and miR-127 activated in OSCC tumors, and,
consistent with previous studies, we found increased DNA
methylation of the miR-137 locus in OSCC patients. However,
miR-137 was below the detection limit in our assays, and FACS
sorting of pure cell populations from patients and normal controls
was required to observe distinct expression and methylation
changes. The miR-200 family and miR-205 are overall epigenet-
ically activated in OSCC tumors, but this may only reflect the
tumor subtype. Rather, we speculate that epigenetically indepen-
dent miR-200/miR-205 repression in oral CD44high cells is an
important event required for oral CSC formation and tumor
progression. Several lines of evidence points to this scenario, but
further work will be required to elucidate the complete regulatory
mechanisms controlling regulation and function of this important
miRNA family. Finally, we show that OSCC specific miRNA and
DNA methylation patterns can be detected and distinguish
between patient oral rinse and saliva. These findings provide a
proof-of-concept, but larger randomized screens are required in
the future to determine how applicable miRNA profiles and DNA
methylation patterns in oral fluids will be as diagnostic predictors
in clinical settings.
Supporting Information
Figure S1 Consistent expression of RNU48 and RNU44
among samples from both patients with oral carcinoma
and healthy volunteers. MiRNA expression profiling was
performed using TaqManH TLDA and included ncRNA reference
genes RNU48 and RNU44. The CT value was presented for the
amplification of RNU48 (Red) and RNU44 (Blue) among samples
from different groups, including 2 non-metastatic tumors (18110T
& 11063T), 2 metastatic tumors (17093T & 28169T), 4 matched
adjacent normal tissues (18110N, 11063N, 17093N & 28169N), 2
healthy connective tissue (stroma) (H14C & H5C) and 2 healthy
epithelium (H14E & H5E), respectively.
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